Image via Wikipedia
Biotech firm InterMune took an ugly hit on Tuesday as news broke that its lung disease drug Esbriet (pirfenidone) will require additional clinical studies, and won’t be getting the seal of approval from FDA any time soon. The news caused InterMune’s stock to drop a staggering 78 percent, according to Reuters. Analysts have [...]
PharmExec Blog
Follow Us
RSS
Bookstore
InterMune Denied Approval for Lung Treatment